Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc

Not Applicable

Completed

• Conditions: Neoplasm Metastasis
• Interventions: Radiation: Volumetric modulated arc therapy

• Registration Number: NCT01218542
• Lead Sponsor: Emory University

Brief Summary

Brain metastases are the most common adult intracranial tumor, occurring in approximately 10% to 30% of adult cancer patients, and represent an important cause of morbidity and mortality. The most widely used treatment for patients with multiple brain metastases is whole brain radiation therapy (WBRT). The use of WBRT after resection or stereotactic radiosurgery (SRS) has been proven to be effective in terms of improving local control of brain metastases.

RapidArc (RA) (Varian Medical Systems, Palo Alto, CA) is a new method of delivering radiation that uses "arcs" to deliver highly conformal intensity modulated three dimensional dose distributions. The purpose of this investigation is to evaluate an alternative strategy for giving WBRT with highly focal boost to gross visible lesions in patients with brain metastasis.

Given the limitations of the SRS boost technique, the purpose of our investigation is to evaluate an alternative strategy for giving WBRT with highly focal boost to gross visible lesions in patients with brain metastasis. In this study, we plan to assess the tolerability of using volumetric modulated arc therapy (RapidArc) on patients with brain metastasis to simultaneously treat the entire brain with a concomitant focal boost to grossly identified lesions on MRI scan to try to improve local control and reduce neurocognitive toxicities.

This previous version of this study was a phase I dose escalation trial giving 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease. Prior to this, patients were enrolled onto one of two cohorts with whole brain dose of 30 Gy in 10 fractions with SIB to total of 45 Gy in 10 fractions to gross brain metastatic disease or whole brain dose of 37.5 Gy in 15 fractions with SIB to total of 52.5 Gy in 15 fractions to gross brain metastatic disease. A total of 12 patients have been previously enrolled on this trial. No patients have experienced a dose limiting toxicity (grade 3 or above) at least possibly due to study therapy. Also, no patients experienced local brain failure/progression at a site of treated metastatic brain disease. Based on this, we no longer feel that dose escalation to the gross brain disease is warranted and would proceed with a single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2010-09-22
• Study First Submitted: 2010-09-30
• Study First Submitted QC: 2010-10-08
• Study First Posted: 2010-10-11
• Primary Completion: 2020-06-03
• Study Completion: 2020-06-03
• Results First Submitted: 2020-06-26
• Status Verified: 2021-06
• Results First Submitted QC: 2021-06-25
• Last Update Submitted: 2021-06-25
• Results First Posted: 2021-06-29
• Last Update Posted: 2021-06-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• Pathologic proven diagnosis of solid tumor malignancy.
• Age ≥ 18.
• KPS ≥ 70.
• Mini Mental Status Exam (MMSE) ≥ 18 prior to study entry.
• RPA class I (KPS ≥ 70, primary cancer controlled, age < 65, metastases in brain only) or class II (lack of one or more of class I criteria).
• One to ten brain metastatic lesions.

Read More

Exclusion Criteria

• Previous whole brain radiation therapy.
• Previous radiosurgery to any currently progressive gross metastatic disease.
• Previous radiosurgery to any intracranial site within the prior 6 weeks.
• Recursive partitioning analysis (RPA) class III (KPS < 70).
• Radiosensitive (eg. small cell lung carcinomas, germ cell tumors, leukemias, or lymphomas) or unknown tumor histologies.
• Concurrent chemotherapy (no chemotherapy starting 14 days before start of radiation).
• Evidence of leptomeningeal disease by MRI and/or cerebrospinal fluid (CSF) cytology.
• Current pregnancy.
• No metastases to brain stem, midbrain, pons, or medulla or within 7 mm of the optic apparatus (optic nerves and chiasm).

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Volumetric modulated arc therapy	Volumetric modulated arc therapy	Single arm pilot study treating patients with 25 Gy in 10 fractions to the whole brain with simultaneous infield boost (SIB) to a total of 45 Gy in 10 fractions to gross brain metastatic disease.

Primary Outcome Measures

Name	Time	Method
Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients	Locoregional control at 1 year	The cumulative incidences of recurrence locally and in the whole brain were reported at the patient level.

Secondary Outcome Measures

Name	Time	Method
Quality of Life as Measured by the FACT-Br Subscales	11 month median follow up	The Functional Assessment of Cancer Therapy-Brain (FACT-Br) were summed to create the FACT brain trial outcome index (FACT-BR TOI), FACT general (FACT-G), and FACT brain total (FACT-BR Total).; Three FACT scales were calculated. The higher the value the better the score, i.e., the better the quality of life perceived by patient.; FACT BR TOTAL (FACT-G + BrCS, possible range 0 - 200) FACT-BR TOI (Trial Outcome Index = Physical Well Being _ Functional Well Being +BrCS, possible range 0 - 148) FACT-G (Fact General, possible range 0 - 108)
Brain Progression-free Survival	11 months median follow up period.	Defined as period of time from study entry to to death from any cause or brain tumor recurrence or progression.
Neurocognitive Effects	11 months median follow up period.	Neurological test score were assessed using the Hopkins Verbal Learning Test-Revised (HVLT).; In the HVLT 12 words are read and the participant is asked to recall them, this is completed 3 times.; Total words recalled are summed to give a score for Total Recall (0-36, higher scores demonstrated better recall).; Delayed recall is conducted 20-25 minutes later on the same list of 12 words (scored 0-12 with higher scores demonstrating better recall).; Retention is calculated as the percent of words recalled (scored 0-100, higher scores representing better recall).; Recognition Discrimination is tested by a series of yes/no responses from the participant identifying 12 target words from a list of 24 and calculated by the number of true positives minus the number of true negatives with higher scores indicating a better outcome.
Overall Survival	11 months median follow up period.	Defined time from study entry to death from any cause.

Trial Locations

Locations (2)

Emory University/Winship Cancer Institute; 🇺🇸 Atlanta, Georgia, United States

Emory University Hospital Midtown; 🇺🇸 Atlanta, Georgia, United States